This Viewpoint discusses the author’s firsthand experience with clinical trials for patients with amyotrophic lateral sclerosis after her husband’s diagnosis.
This Viewpoint discusses the emerging field of deprescribing and how to advance deprescribing among patients with epilepsy.
This essay describes the experience of a medical student encountering a mother whose son was terminally ill with Lafora body disease.
This study investigates the neurologic manifestations of patients with coronavirus disease 2019.
This cohort study examines a system for prehospital triage for Swedish patients with suspected acute stroke.
This cohort study analyzes Swedish patient registries to identify the familial, lifestyle, cardiovascular, and other risk factors in the later development of neurodegenerative diseases among adults with stress-related disorders compared with their siblings and people without the condition.
This cohort study evaluates whether incident late-onset unprovoked seizures of unknown etiology are associated with a higher risk of developing dementia among older US veterans.
This cross-sectional study seeks to determine which brain changes, including changes in amyloid deposition, gray matter volume, perfusion, and glucose metabolism, are associated with the presence of sleep-disordered breathing in older individuals who are cognitively unimpaired.
This randomized clinical trial examines whether in-hospital treatment with remote ischemic perconditioning that is administered within 6 hours of symptom onset, with or without reperfusion therapy, can reduce brain infarction volume growth in patients with acute ischemic stroke.
This cross-sectional analysis examines the association of elevated amyloid with demographic and lifestyle factors, apolipoprotein E, neuropsychological testing, and self- and study partner reports of cognitive function among participants in the A4 Study.
This genetic association study compares gene loci for Parkinson Disease in cohorts of Asian and European individuals with Parkinson disease.
This Special Communication discusses the formation of the National Institute of Neurological Disorders and Stroke Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) and what NeuroNEXT has accomplished within the first 7 years.
This review examines data from human and animal studies of the altered huntingtin protein associated with Huntington disease to assess the risk-benefit profile of huntingtin-lowering therapies for the treatment of people with Huntington disease.
Create a personal account or sign in to: